{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:25:37Z","timestamp":1762917937653,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Fresenius Medical Care Renal Therapies Group"},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011611","name":"ASN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011611","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astra-Zeneca"},{"name":"AVEO"},{"DOI":"10.13039\/100010795","name":"Chugai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DaVita"},{"DOI":"10.13039\/501100003389","name":"Fresenius","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Haymarket Media"},{"name":"Hofstra Medical School"},{"name":"IFKF"},{"DOI":"10.13039\/100011054","name":"ISH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Society of Renal Nutrition & Metabolism"},{"name":"JSDT"},{"name":"Hospira"},{"name":"Kabi"},{"name":"Keryx"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OPKO"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001353","name":"NKF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Relypsa"},{"name":"Resverlogix"},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UpToDate"},{"name":"ZS-Pharma"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jrnjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Renal Nutrition"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1053\/j.jrn.2018.11.002","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T13:29:23Z","timestamp":1548077363000},"page":"428-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis"],"prefix":"10.1053","volume":"29","author":[{"given":"Jessica","family":"Kendrick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8461-1797","authenticated-orcid":false,"given":"Vidhya","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda H.","family":"Ficociello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma J.","family":"Ofsthun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudy","family":"Mullon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Kossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-0725","authenticated-orcid":false,"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jrn.2018.11.002_bib1","first-page":"141","article-title":"Patient-reported factors associated with poor phosphorus control in a maintenance hemodialysis population","volume":"26","author":"Joson","year":"2016","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1053\/j.jrn.2018.11.002_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","article-title":"Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphatemia: a randomized, open-label, multicentre, 12-week phase III study","volume":"22","author":"Koiwa","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"10.1053\/j.jrn.2018.11.002_bib3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jsps.2015.01.009","article-title":"Hyperphosphatemia management in patients with chronic kidney disease","volume":"24","author":"Shaman","year":"2016","journal-title":"Saudi Pharm J"},{"key":"10.1053\/j.jrn.2018.11.002_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS","volume":"20","author":"Fissell","year":"2016","journal-title":"Hemodial Int"},{"key":"10.1053\/j.jrn.2018.11.002_bib5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14740338.2014.907791","article-title":"Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles","volume":"13","author":"Locatelli","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1053\/j.jrn.2018.11.002_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 3","key":"10.1053\/j.jrn.2018.11.002_bib7","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2018.11.002_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.jrn.2018.11.002_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semnephrol.2012.12.018","article-title":"Management of natural and added dietary phosphorus burden in kidney disease","volume":"33","author":"Cupisti","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.jrn.2018.11.002_bib10","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2018.11.002_bib11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2018.11.002_bib12","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.2004040275","article-title":"Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study","volume":"16","author":"Slinin","year":"2005","journal-title":"J Am Soc Nephrol"},{"year":"2017","series-title":"Serum phosphorous (most recent)","key":"10.1053\/j.jrn.2018.11.002_bib13"},{"key":"10.1053\/j.jrn.2018.11.002_bib14","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/ndt\/gfw460","article-title":"One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis","volume":"32","author":"Floege","year":"2017","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.jrn.2018.11.002_bib15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/sdi.12412","article-title":"Novel therapeutic options for the treatment of mineral metabolism abnormalities in end stage renal disease","volume":"28","author":"Kendrick","year":"2015","journal-title":"Semin Dial"},{"key":"10.1053\/j.jrn.2018.11.002_bib16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.jrn.2018.11.002_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10157-016-1299-z","article-title":"Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study","volume":"21","author":"Koiwa","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.jrn.2018.11.002_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.jrn.2016.01.009","article-title":"An update on phosphate binders: a dietitian's perspective","volume":"26","author":"Gutekunst","year":"2016","journal-title":"J Ren Nutr"},{"key":"10.1053\/j.jrn.2018.11.002_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5414\/CN109021","article-title":"Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data","volume":"88","author":"Coyne","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.jrn.2018.11.002_bib20","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/ndt\/15.11.1841","article-title":"Albumin-corrected calcium and ionized calcium in stable haemodialysis patients","volume":"15","author":"Clase","year":"2000","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.jrn.2018.11.002_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000487856","article-title":"Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide","volume":"47","author":"Kalantar-Zadeh","year":"2018","journal-title":"Am J Nephrol"},{"year":"2017","series-title":"2017 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States","key":"10.1053\/j.jrn.2018.11.002_bib22"},{"key":"10.1053\/j.jrn.2018.11.002_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2018.11.002_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000438999","article-title":"Race, mineral homeostasis and mortality in patients with end-stage renal disease on dialysis","volume":"42","author":"Scialla","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.jrn.2018.11.002_bib25","first-page":"10","article-title":"Serum phosphorus levels, race, and socioeconomic status in incident hemodialysis patients","volume":"26","author":"Kumar","year":"2016","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1053\/j.jrn.2018.11.002_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ackd.2013.06.007","article-title":"Women and CKD-mineral and bone disorder","volume":"20","author":"Ho","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.jrn.2018.11.002_bib27","doi-asserted-by":"crossref","first-page":"e1001750","DOI":"10.1371\/journal.pmed.1001750","article-title":"Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"11","author":"Hecking","year":"2014","journal-title":"PLoS Med"},{"year":"2017","series-title":"Velphoro (Sucroferric Oxyhydroxide) [package insert]","key":"10.1053\/j.jrn.2018.11.002_bib28"},{"key":"10.1053\/j.jrn.2018.11.002_bib29","first-page":"1330","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.jrn.2018.11.002_bib30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/j.jrn.2018.11.002_bib31","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2215\/CJN.04620510","article-title":"Prescribed dietary phosphate restriction and survival among hemodialysis patients","volume":"6","author":"Lynch","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2018.11.002_bib32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2215\/CJN.13141216","article-title":"Longitudinal associations among renal urea clearance-corrected normalized protein catabolic rate, serum albumin, and mortality in patients on hemodialysis","volume":"12","author":"Eriguchi","year":"2017","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of Renal Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227618302541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227618302541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:33:56Z","timestamp":1760942036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051227618302541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1051227618302541"],"URL":"https:\/\/doi.org\/10.1053\/j.jrn.2018.11.002","relation":{},"ISSN":["1051-2276"],"issn-type":[{"type":"print","value":"1051-2276"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Renal Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jrn.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}